Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men With High-Risk PSA-Recurrent Prostate Cancer After Radical Prostatectomy
Latest Information Update: 02 Jun 2023
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms SALV-ENZA
- 30 May 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 20 Jan 2023 Planned End Date changed from 10 Jan 2023 to 1 Dec 2023.
- 11 Nov 2022 Results assessing efficacy and safety of salvage radiation therapy plus enzalutamide in men with recurrent prostate cancer after radical prostatectomy, published in the Journal of Clinical Oncology.